L Wu, MA Martínez-Castellanos, H Quiroz- … - Graefe's Archive for Clinical and Experimental …, 2008 - Springer Abstract Background Vascular endothelial growth factor (VEGF) plays an important
role in many diseases of the posterior pole that are characterized by macular
edema and/or intraocular neovascularization. Recently anti-VEGF agents such ... Cited by 65 - Related articles - BL Direct - All 2 versions
R Pedersen, W Soliman, H Lund-Andersen, M … - Acta Ophthalmologica Scandinavica, 2007 - duanesolution.com Methods: A retrospective observational, uncontrolled case series including 26
eyes in 25 patients followed for up to 6 months after intravitreal injection of
bevacizumab 1 mg repeated as deemed necessary after monthly assessments by ... Cited by 38 - Related articles - Cached - BL Direct - All 5 versions
P Algvere, B Steen, S Seregard, A Kvanta… - Acta Ophthalmologica, 2008 - interscience.wiley.com Methods: The case material comprised 36 subjects (26 females, 10 males) aged
65–88 years with subfoveal neovascular AMD with all subtypes of CNV. There
were two categories of patients: category I, long-standing CNV (12 months ... Cited by 29 - Related articles - All 4 versions
JB Jonas, T Libondi, AK Ihloff, B Harder, I … - Acta Ophthalmologica Scandinavica, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 26 - Related articles - BL Direct - All 3 versions
- ►duanessolution.com E Yoeruek, MS Spitzer, O Tatar, S Aisenbrey, … - Cornea, 2007 - journals.lww.com Methods: Cell cultures of corneal keratinocytes (CKs), corneal fibroblasts
(CFs), and corneal endothelial cells (CECs) were har- vested from human donor
eyes and exposed to various concentra- tions of bevacizumab (0.25–5.0 ... Cited by 26 - Related articles - BL Direct - All 4 versions
- ►iovs.org UU Inan, B Avci, T Kusbeci, B Kaderli, R Avci … - Investigative Ophthalmology & Visual Science, 2007 - ARVO METHODS. Twenty-four rabbits were divided into two groups, each with two
subgroups. The first group (groups 1 and 2) received 1.25 mg (0.05 mL)
intravitreal bevacizumab, and the second group (groups 3 and 4) received ... Cited by 26 - Related articles - BL Direct - All 3 versions
MS Spitzer, E Yoeruek, A Sierra, B … - Graefe's Archive for Clinical and Experimental …, 2007 - Springer Page 1. RETINAL DISORDERS Comparative antiproliferative and cytotoxic profile
of bevacizumab (Avastin), pegaptanib (Macugen) and ... Cited by 23 - Related articles - BL Direct - All 2 versions
R Shetty, SA Pai, A Vincent, N Shetty, KM … - Documenta Ophthalmologica, 2008 - Springer Abstract Purpose To evaluate with electrophysio- logical responses and Optical
Coherence Tomography (OCT), the short term functional and structural effects at
the macula following intravitreal injection of bevacizumab for macular ... Cited by 11 - Related articles - BL Direct - All 2 versions
P Heiduschka, S Julien, S Hofmeister, KU … - Retina, 2008 - journals.lww.com From the †Centre of Ophthalmology and *Experimental Vitreo- retinal Surgery,
University of Tübingen Eye Hospital, Germany. None of the authors has
proprietary interest. Presented in part at the annual ARVO meeting; May ... Cited by 10 - Related articles - BL Direct - All 3 versions
- ►prsjournal.com PJ Rosenfeld - British Journal of Ophthalmology, 2007 - bjo.bmj.com The same progression of events is now taking place in the use of Avastin for CNV
secondary to pathological myopia. Last year, Nguyen et al 27 reported on the use
of systemic Avastin for the treatment of subfoveal CNV secondary to ... Cited by 10 - Related articles - BL Direct - All 7 versions
